Skip to main content

SLE

2
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Ascentage Pharma
Ascentage PharmaChina - Beijing
1 program
1
APG-2575Phase 1/21 trial
Active Trials
NCT06182969Recruiting40Est. Dec 2026
Cullinan Therapeutics
Cullinan TherapeuticsMA - Cambridge
1 program
1
CLN-978Phase 11 trial
Active Trials
NCT06613360Recruiting24Est. Dec 2027
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
CIMT and baPWV measurementN/A1 trial
Active Trials
NCT04037293Unknown500Est. Dec 2021
Pfizer
PfizerNEW YORK, NY
1 program
No Medical InterventionN/A
Alliance Pharmaceuticals
1 program
No Medical InterventionN/A1 trial
Active Trials
NCT03142711Completed80Est. Jul 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Ascentage PharmaAPG-2575
Cullinan TherapeuticsCLN-978
Alliance PharmaceuticalsNo Medical Intervention
UNION therapeuticsCIMT and baPWV measurement

Clinical Trials (4)

Total enrollment: 644 patients across 4 trials

NCT06182969Ascentage PharmaAPG-2575

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Start: Aug 2024Est. completion: Dec 202640 patients
Phase 1/2Recruiting
NCT06613360Cullinan TherapeuticsCLN-978

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Start: Jan 2025Est. completion: Dec 202724 patients
Phase 1Recruiting
NCT03142711Alliance PharmaceuticalsNo Medical Intervention

Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus

Start: Aug 2017Est. completion: Jul 201880 patients
N/ACompleted
NCT04037293UNION therapeuticsCIMT and baPWV measurement

Premature Atherosclerosis in Systemic Lupus Erythematosus

Start: May 2013Est. completion: Dec 2021500 patients
N/AUnknown

Related Jobs

Senior Scientist, Vaccines Analytical R&D

Merck & Co.Merck & Co.
USA - Pennsylvania - West Point (Not Applicable)
2w ago
$117K - $184K/yr

Global Regulatory Lead, Immunology Expansion, WCH

BiogenBiogen
San Francisco, CA (Hybrid)
3w ago
$246K - $338K/yr

Program Lead - Method Remediation (Animal Health)

Merck & Co.Merck & Co.
USA - Nebraska - Elkhorn; USA - Delaware - Millsboro (Intervet); USA - Kansas - De Soto (Hybrid)
3w ago
$129K - $203K/yr

Associate Director, Associate Director, Forecasting, US & WW Pipeline Immunology

Bristol Myers SquibbBristol Myers Squibb
Princeton - NJ - US
3w ago
$168K - $203K/yr

Intern – (medical) biotechnology – Bio Technology Solutions (BTS)

Merck & Co.Merck & Co.
NLD - North Brabant - Boxmeer (Not Applicable)
3w ago

Intern Molecular Biology- Bachelor/Master - Discovery & Technology

Merck & Co.Merck & Co.
NLD - North Brabant - Boxmeer (Not Applicable)
3w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 644 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.